Editorial

Device-based therapies for resistant hypertension in chronic kidney disease: The continuing quest for a cure

George Thomas, MD
Cleveland Clinic Journal of Medicine July 2020, 87 (7) 444-447; DOI: https://doi.org/10.3949/ccjm.87a.20092

This article has a correction. Please see:

PDF extract preview

You do not have access to the full text of this article, the first page of the PDF of this article appears above.

REFERENCES

  1. ↵
    1. Thomas G,
    2. Xie D,
    3. Chen HY, et al; CRIC Study Investigators
    . Prevalence and prognostic significance of apparent treatment resistant hypertension in chronic kidney disease: report from the Chronic Renal Insufficiency Cohort Study. Hypertension 2016; 67(2):387–396. doi:10.1161/HYPERTENSIONAHA.115.06487
    OpenUrlCrossRefPubMed
  2. ↵
    1. Gajulapalli RD,
    2. Chahine J,
    3. Rader F,
    4. Aneja A
    . Procedures and devices to treat resistant hypertension in chronic kidney disease. Cleve Clin J Med 2020; 87(7):435–443. doi:10.3949/ccjm.87a.19099
    OpenUrlAbstract/FREE Full Text
  3. ↵
    1. Bhatt DL,
    2. Kandzari DE,
    3. O’Neill WW, et al; SYMPLICITY HTN-3 Investigators
    . A controlled trial of renal denervation for resistant hypertension. N Engl J Med 2014; 370(15):1393–1401. doi:10.1056/NEJMoa1402670
    OpenUrlCrossRefPubMed
  4. ↵
    1. Kandzari DE,
    2. Böhm M,
    3. Mahfoud F, et al; SPYRAL HTN-ON MED Trial Investigators
    . Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trial. Lancet 2018; 391(10137):2346–2355. doi:10.1016/S0140-6736(18)30951-6
    OpenUrlCrossRefPubMed
  5. ↵
    1. Townsend RR,
    2. Mahfoud F,
    3. Kandzari DE, et al; SPYRAL HTN-OFF MED Trial Investigators
    . Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trial. Lancet 2017; 390(10108):2160–2170. doi:10.1016/S0140-6736(17)32281-X
    OpenUrlCrossRef
  6. ↵
    1. Azizi M,
    2. Schmieder RE,
    3. Mahfoud F, et al; RADIANCE-HTN Investigators
    . Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet 2018; 391(10137):2335–2345. doi:10.1016/S0140-6736(18)31082-1
    OpenUrlCrossRefPubMed
  7. ↵
    1. Azizi M,
    2. Sapoval M,
    3. Gosse P, et al; Renal Denervation for Hypertension (DENERHTN) investigators
    . Optimum and stepped care standardised antihypertensive treatment with or without renal denervation for resistant hypertension (DENERHTN): a multi-centre, open-label, randomised controlled trial. Lancet 2015; 385(9981):1957–1965. doi:10.1016/S0140-6736(14)61942-5
    OpenUrlCrossRefPubMed
  8. ↵
    1. Sardar P,
    2. Bhatt DL,
    3. Kirtane AJ, et al
    . Sham-controlled randomized trials of catheter-based renal denervation in patients with hypertension. J Am Coll Cardiol 2019; 73(13):1633–1642. doi:10.1016/j.jacc.2018.12.082
    OpenUrlFREE Full Text
  9. ↵
    1. Cheng X,
    2. Zhang D,
    3. Luo S,
    4. Qin S
    . Effect of catheter based renal denervation on uncontrolled hypertension: a systematic review and meta-analysis. Mayo Clin Proc 2019; 94(9):1695–1706. doi:10.1016/j.mayocp.2019.07.005
    OpenUrlCrossRef
  10. ↵
    1. Hering D,
    2. Mahfoud F,
    3. Walton AS, et al
    . Renal denervation in moderate to severe CKD. J Am Soc Nephrol 2012; 23(7):1250–1257. doi:10.1681/ASN.2011111062
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Prasad B,
    2. Berry W,
    3. Goyal K,
    4. Dehghani P,
    5. Townsend RR
    . Central blood pressure and pulse wave velocity changes post renal de-nervation in patients with stages 3 and 4 chronic kidney disease: the Regina RDN Study. Can J Kidney Health Dis 2019 Feb 13; 6:2054358119828388. doi:10.1177/2054358119828388
    OpenUrlCrossRef
  12. ↵
    1. Mahfoud F,
    2. Böhm M,
    3. Schmieder R, et al
    . Effects of renal denervation on kidney function and long-term outcomes: 3-year follow-up from the Global SYMPLICITY Registry. Eur Heart J 2019; 40(42):3474–3482. doi:10.1093/eurheartj/ehz118
    OpenUrlCrossRef
  13. ↵
    1. Spiering W,
    2. Williams B,
    3. Van der Heyden J, et al; CALM-FIM_EUR investigators
    . Endovascular baroreflex amplification for resistant hypertension: a safety and proof-of-principle clinical study. Lancet 2017; 390(10113):2655–2661. doi:10.1016/S0140-6736(17)32337-1
    OpenUrlCrossRef
  14. ↵
    1. Peixoto AJ
    . Is there a role for device therapies in resistant hypertension? The CON side. Kidney360 January 2020; 1(1):9–13. doi:10.34067/KID.0000742019
    OpenUrlCrossRef
  15. ↵
    1. Cooper CJ,
    2. Murphy TP,
    3. Cutlip DE, et al; CORAL Investigators
    . Stenting and medical therapy for atherosclerotic renal-artery stenosis. N Engl J Med 2014; 370(1):13–22. doi:10.1056/NEJMoa1310753
    OpenUrlCrossRefPubMed
  16. ↵
    1. Textor SC,
    2. Lerman LO
    . Reality and renovascular disease: when does renal artery stenosis warrant revascularization? Am J Kidney Dis 2014; 63(2):175–177. doi:10.1053/j.ajkd.2013.11.004
    OpenUrlCrossRefPubMed
  17. ↵
    1. Williams B,
    2. MacDonald TM,
    3. Morant S, et al; British Hypertension Society’s PATHWAY Studies Group
    . Spironolactone versus placebo, bisoprolol, and doxazosin to determine the optimal treatment for drug-resistant hypertension (PATHWAY-2): a randomised, double-blind, crossover trial. Lancet 2015; 386(10008):2059–2068. doi:10.1016/S0140-6736(15)00257-3
    OpenUrlCrossRefPubMed
  18. ↵
    1. Oliveras A,
    2. Armario P,
    3. Clarà A, et al
    . Spironolactone versus sympathetic renal denervation to treat true resistant hypertension: results from the DENERVHTA study — a randomized controlled trial. J Hypertens 2016; 34(9):1863–1871. doi:10.1097/HJH.0000000000001025
    OpenUrlCrossRef
  19. ↵
    1. Rosa J,
    2. Widimský P,
    3. Waldauf P, et al
    . Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertension: 2-year outcomes of randomized PRAGUE-15 study. J Hypertens 2017; 35(5):1093–1099. doi:10.1097/HJH.0000000000001257
    OpenUrlCrossRef
  20. ↵
    1. Agarwal R,
    2. Rossignol P,
    3. Romero A, et al
    . Patiromer versus placebo to enable spironolactone use in patients with resistant hypertension and chronic kidney disease (AMBER): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet 2019; 394(10208):1540–1550. doi:10.1016/S0140-6736(19)32135-X
    OpenUrlCrossRefPubMed

This article requires you to have a ccjm.org account to view the full text. If you already have an account, you may log in below to view this article along with all other CCJM content. If you do not have an account, register here. It’s free!

Back to top

Registration is Now Required for Free Access to CCJM Content

Register once and log in for full access to articles and content. Click “Register” in the upper right corner and follow the simple instructions to create a new account.

If you are using a mobile device, click on the settings icon to access the Register link.

In this issue

Print
Download PDF
Article Alerts
Email Article
Citation Tools

Jump to section